Braveheart Bio, Inc. reported that investment entities associated with AH Bio Fund IV converted preferred shares and purchased additional common stock. On August 7, 2026, 40,000,000 shares of Series A Preferred Stock automatically converted into 9,132,420 shares of Common Stock immediately prior to the closing of the company’s initial public offering, on a 4.38-for-1 basis for no additional consideration. The preferred shares, which had no expiration date, are now fully converted.
On the same date, AH Bio Fund IV, L.P., for itself and as nominee for several related funds, purchased 1,100,000 shares of Common Stock at $18.00 per share, reported as indirectly owned. AH Equity Partners Bio IV, L.L.C. is the general partner of AH Bio Fund IV and has sole voting and dispositive power over these securities. Marc Andreessen and Ben Horowitz are managing members of AH Equity Partners Bio IV and may be deemed to share voting and dispositive power, but each reporting person disclaims beneficial ownership of the securities beyond any pecuniary interest.
Braveheart Bio, Inc. director and greater-than-10% owner Erez Chimovits, through OrbiMed-affiliated entities, reported several indirect transactions on August 7, 2026 tied to the company’s initial public offering. 40,000,000 shares of Series A Preferred Stock automatically converted into 9,132,420 shares of Common Stock on a one-for-4.38 basis upon the IPO closing, without payment of consideration, eliminating the reported Series A Preferred position. In the same IPO, OrbiMed-related funds indirectly purchased an additional 1,666,667 and 273,333 shares of Common Stock at $18.00 per share. The securities are held of record by OrbiMed Private Investments IX, LP and OrbiMed Genesis Master Fund, L.P., with OrbiMed entities exercising voting and investment power, and all parties, including the reporting person, disclaiming beneficial ownership beyond any pecuniary interest.
Braveheart Bio, Inc. received updated ownership reporting from OrbiMed-affiliated entities in connection with its initial public offering on August 7, 2026. 40,000,000 shares of Series A Preferred Stock automatically converted, on a one-for-4.38 basis and without additional consideration, into 9,132,420 shares of common stock. OrbiMed-related funds also purchased 1,666,667 and 273,333 common shares at $18.00 per share in the IPO. The securities are held indirectly through OrbiMed Private Investments IX, LP and OrbiMed Genesis Master Fund, L.P., with OrbiMed Advisors LLC and its affiliated general partners deemed to have voting and investment power and all reporting persons disclaiming beneficial ownership beyond their pecuniary interest.
Jiangsu Hengrui Pharmaceuticals Co., Ltd., a more-than-10% owner of Braveheart Bio, Inc., reported a conversion of its holdings. On 2026-08-07, it converted 32,500,000 shares of non-voting Series A preferred stock into 7,420,091 shares of common stock, consistent with terms that provide for automatic conversion immediately prior to the closing of Braveheart Bio’s initial public offering. Following the transactions, Jiangsu Hengrui directly holds 7,420,091 shares of common stock and no remaining shares of the non-voting Series A preferred stock.
Braveheart Bio, Inc. reported that investment entities affiliated with Forbion converted 75,000,000 shares of Series A Preferred Stock into 17,123,287 shares of Common Stock on August 7, 2026, in connection with the closing of the initial public offering, at a 1-for-4.38 conversion rate without additional consideration. On the same date, these Forbion entities also purchased 3,600,000 Common Shares at $18.00 per share in open-market or private transactions. Footnotes state that the management entities may be deemed to have voting and dispositive power over the fund holdings and that each reporting person disclaims Section 16 beneficial ownership except to the extent of its pecuniary interest.
Braveheart Bio, Inc. Chief Financial Officer Rickey James Paul purchased 27,777 shares of Common Stock on August 7, 2026 at $18.00 per share, bringing his directly held Common Stock to 520,927 shares. On August 5, 2026 he also received a stock option grant for 300,000 shares of Common Stock at an exercise price of $18.00 per share, expiring on August 4, 2036, with 1/48 of the option vesting monthly starting July 23, 2026, subject to continued service. Additional Common Stock is held indirectly through Rickey Trust CR and Rickey Trust BR, with 91,324 shares reported after the transaction for each trust; he disclaims beneficial ownership of those trust-held securities except to the extent of any pecuniary interest.
Braveheart Bio, Inc. director Lohoff Tim reported a grant of stock options on August 5, 2026. The award covers 30,000 Stock Options (Right to Buy) with an exercise price of $18.00 per share, expiring on August 4, 2036. These options, representing 30,000 underlying common shares, were acquired at a grant price of $0.00 and are held as direct ownership. According to the award terms, all shares underlying the option will vest in full on the earlier of August 5, 2027 or the date of the issuer's next annual stockholder meeting, conditioned on the reporting person's continued service to the company through that vesting date.
Braveheart Bio, Inc. reported that director and 10% owner Erez Chimovits received a grant of 30,000 stock options to acquire Braveheart Bio common stock at an exercise price of $18.00 per share. These options, which now total 30,000 derivative securities held directly, expire on August 4, 2036. The shares underlying the option will vest in full on the earlier of August 5, 2027 or the date of the company’s next annual stockholders’ meeting, subject to his continued service. Under a separate agreement, any securities or economic benefits from these options are to be transferred to OrbiMed Advisors LLC for the benefit of OrbiMed Private Investments IX, LP.
Braveheart Bio, Inc. director Christopher Viehbacher reported buying 83,333 shares of common stock at $18.00 per share on August 7, 2026, bringing his direct holdings to 609,519 shares. He also received a stock option for 30,000 shares at an exercise price of $18.00, expiring August 4, 2036; these options vest in full on the earlier of August 5, 2027 or the next annual stockholders’ meeting, subject to continued service. In addition, 150,338 shares are held indirectly through CAV FAMILY LLC, with beneficial ownership disclaimed except for any pecuniary interest.
Braveheart Bio, Inc. director David I. Malek reported two equity-related events. On August 7, 2026 he purchased 4,166 shares of Common Stock at $18.00 per share, bringing his directly held Common Stock to 533,845 shares. On August 5, 2026 he also received a grant of stock options for 30,000 shares of Common Stock with an exercise price of $18.00 per share, expiring on August 4, 2036; these options vest in full on the earlier of August 5, 2027 or the date of the company’s next annual stockholder meeting, subject to his continued service. In addition, 239,726 shares are reported as held indirectly by Malek Trust YM and 239,726 shares by Malek Trust NM, with beneficial ownership disclaimed except for any pecuniary interest.